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Abstract Background: Dopamine receptor D2 (DRD2)
polymorphisms are proposed to be important factors in
the presentation of neuropsychiatric symptoms in many
disorders, including decreased striatum levels of dopamine
D2 receptors in Wilson disease. The present study inves-
tigated the association between DRD2 gene polymorphisms
and clinical manifestation of Wilson disease.
Methods: Analyzing data from 97 symptomatic Wilson
disease patients, we investigated the DRD2 gene poly-
morphisms rs1800497, rs1799732, and rs12364283. We
assessed the polymorphisms impact on the phenotypic
presentation of the disease.
Results: Generally, the DRD2 gene polymorphisms had
no impact on the hepatic or neuropsychiatric clinical
presentation of Wilson disease. However, rs1799732
deletion allele carriers with neuropsychiatric symptoms
had earlier onset of WD symptoms by almost 6 years
compared with individuals without this allele (22.5 vs.
28.3 years; P < 0.05). This unfavorable effect of the
rs1799732 polymorphism was even more pronounced
among adenosine triphosphatase 7B gene (ATP7B)
p.H1069Q homozygous patients, in whom carriership of
the deletion allele was related to earlier initial neuro-
psychiatric manifestation by 14 years (18.4 vs. 32.2 years;
P < 0.01).
Conclusions: Genetic variation of DRD2, specifically the
rs1799732 polymorphism, may produce an earlier clinical
presentation of Wilson disease neuropsychiatric symptoms
and signs that occur in the course of dopaminergic system
impairment due to copper accumulation in the brain. We
speculate that this effect may be due to the impact of DRD2
polymorphism on dopamine D2 receptor density, but
further studies are needed to understand the mechanisms
of such phenotypic effects.
Introduction
Wilson disease (WD) is an inherited copper metabolism
disorder leading to copper accumulation in many tissues
(mainly the liver and brain) with secondary damage to
affected organs (Roberts and Schilsky 2008; Ala et al. 2007;
Ferenci et al. 2003, 2007). WD is associated with a wide
spectrum of symptoms (hepatic, neurological, psychiatric,
and others) as well as great variability in clinical presentation
and outcome (Roberts and Schilsky 2008; Ala et al. 2007;
Ferenci et al. 2003, 2007; Schilsky et al. 1994). Although
these differences remain largely unexplained, several factors
are known to impact clinical presentation of WD, including
gender (Schilsky et al. 1994; Litwin et al. 2012a) and
genotype (Stapelbroek et al. 2004; Gromadzka et al. 2005,
2006). It is also suspected that WD presentation may
be influenced by polymorphisms in the genes encoding
prion-related protein, methylenetetrahydrofolate reductase,
interleukin-1 receptor antagonist, and apolipoprotein-E
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(Merle et al. 2006; Gromadzka et al. 2011a, b; Schiefermeier
et al. 2000; Litwin et al. 2012b). Other genes like
antioxidant-1 (Atox-1), copper metabolism gene MURR1
domain containing proteins (COMMD), and X-linked
inhibitor of apoptosis (XIAP) (Simon et al. 2008; Weiss
et al. 2006; Burstein et al. 2005; Weiss et al. 2010) have also
been suggested as WD modifiers. Nonetheless, phenotype-
related differences in WD manifestation are still mainly
unknown.
In WD, most of the neuropsychiatric symptoms are due to
basal ganglia dysfunction secondary to copper accumulation
(Magalhaes et al. 1994; Schlaug et al. 1994; Nyberg et al.
1982). Pathology studies in WD revealed reduced striatal
dopamine and hydroxylase tyrosine levels (Vallone et al.
2000; Nyberg et al. 1982; Mousseau et al. 1993) and animal
studies have indicated decreased dopamine receptor 2 (DRD2)
during copper overloading (de Vries et al. 1986). Single
photon emission computerized tomography (SPECT) and
positron emission tomography (PET) studies have shown
postsynaptic dopaminergic deficit (loss of D2 receptors in
striatum) in WD patients (Oder et al. 1996; Westermark
et al. 1995) as well as presynaptic nigrostratial dopaminer-
gic damage (Jeon et al. 1998). WD patients also exhibit
reduced bindings of dopamine ligands to dopamine recep-
tors on lymphocytes probably due to dopamine receptors
damage during copper intoxication (Członkowski and
Członkowska 1984; Członkowska et al. 1987).
Polymorphisms in the DRD2 gene and the related
ankyrin repeat and protein kinase–containing protein
(ANKK) gene – including ANKK TaqIA (rs1800497),
DRD2 PROM 141 C Ins/Del (rs1799732), and DRD2
Ex8 (rs12364283) – impact the dopamine receptor D2
density in the striatum with a high clinical significance in
the etiology of many neuropsychiatric disorders, especially
involuntary movements (Table 1) (Wu et al. 2006; Noble
2003; Thompson et al. 1997; Kisihida et al. 2004; Suzuki
et al. 2001; Tan et al. 2003; Zhang et al. 2010; Ritchie and
Noble 2003; Farde and Nordstrom 1993; Farde et al. 1995,
1997; Tinsley et al. 2009).
We hypothesized that these polymorphisms may repre-
sent an important predicting factor for phenotypic manifes-
tations of WD. The aim of the present study was to
determine, in a large group of WD patients, the relation-
ships among these three important DRD2-related single
nucleotide polymorphisms (SNPs) and WD presentation.
Methods
We studied 97 WD symptomatic patients (42 men and 55
women) who had received a confirmed diagnosis from the
Institute of Psychiatry and Neurology in Warsaw, Poland,
between 1988 and 2010. This study was approved by the
local ethics committee and informed consent was provided
by all study subjects. The diagnoses were based on clinical
symptoms, abnormal copper metabolism (decreased levels
of serum ceruloplasmin and serum copper, and increased
24-h urine copper excretion), presence of the Kayser-
Fleischer ring, and, in many cases, genetic examination. If
the diagnosis was not certain, it was confirmed by
measuring Cu-64 incorporation into ceruloplasmin after
24 and 48 h. None of the examined patients were treated
with neuroleptics or drugs that could interfere with
dopamine metabolism (dopamine agonists, levodopa),
Table 1 DRD2 polymorphisms and their possible clinical significance
Polymorphism Possible clinical significance Comment
rs1800497 ANKK TaqIA The A1 allele frequency is higher in patients with neuroleptic
malignant syndrome (Suzuki et al. 2001).
The A1 allele may be associated with
decreased D2 receptors in striatum
(Noble 2003).The A1 allele is associated with tardive dyskinesia, Parkinson’s
disease (data are conflicting), and late onset hallucination
induced by treatment with levodopa (Noble 2003; Makoff
et al. 2000; Olivieri et al. 2000).
rs1799732 141 C Ins/Del The Del allele frequency is higher in patients with neuroleptic
malignant syndrome (mechanism not known; data
conflicting) (Kishida et al. 2004; Farde et al. 1995).
The Del allele is significantly associated with poorer
antipsychotic drug response (Zhang et al. 2010).
Data are conflicting regarding the impact
on D2 receptors density in striatum
Deletion (Del+) may be associated with
increased number of D2 receptors
(Jonsson et al. 1999) or may have no
impact on DRD2 density (Ritchie and
Noble 2003).
rs12364283 DRD2 Ex8 DRD2 Ex8 A/A genotype is associated with increased anxiety,
depression, and suicide attempts after detoxification treatment
in alcohol-dependent patients, with reduced response to
dopamine D2 agonists (apomorphine) and to D2 antagonists
(tiapride) (Samochowiec et al. 2000).
The E8A/A allele may be associated with
reduced DRD2 expression (Samochowiec
et al. 2000).
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as such treatment could produce neuropsychiatric manifes-
tations, such as drug-induced movement disorders.
Symptomatic WD patients were defined as patients with
clinical signs of WD at onset and/or diagnosis. The hepatic
symptoms and signs were assessed based on a detailed
questionnaire that included data on fatigue, weight loss, leg
edema, jaundice, abdominal swelling, hematemesis, hem-
orrhages, and fulminant liver failure. Laboratory examina-
tions included ultrasound examinations of the liver and
spleen, gastroscopy, and assessments of aminotransferases,
alkaline phosphatase, bilirubin, INR, and albumen that were
available from medical history and records. The evaluation
of neuropsychiatric symptoms and signs was also based on
a detailed questionnaire addressing salivation, dysphagia,
speech, writing and gait disturbances, involuntary move-
ments, adynamia, epileptic seizures, mood disorders,
anxiety, and cognitive impairment (Litwin et al. 2012a).
The age at WD symptom onset/diagnosis was assessed
based on patient history, symptoms and signs of WD, and/
or available medical documentation in addition to clinical
and laboratory investigations.
WD genotyping was determined by polymerase chain
reaction (PCR) as reported previously (Gromadzka et al.
2005, 2006) and was assessed according to ATP7B genotype
(homozygous p.H1069Q/p.H1069Q, compound heterozygous
p.H1069Q/other mutation, or negative for the p.H0169Q
mutation). Polymorphisms were determined by PCR and
restriction fragment length polymorphism analysis of ANKK
TaqIA (rs1800497), DRD2 PROM –141 C Ins/Del
(rs1799732), and DRD2 Ex8 (rs12364283) as previously
described (Grandy et al. 1989; Hori et al. 2001; Samochowiec
et al. 2000). Investigated SNPs, primers, and PCR products
are presented in Table 2. One hundred (50 males and
50 females) unrelated, matched, healthy controls were used
for SNP comparison and to check the Hardy–Weinberg
equilibrium.
Due to the clinical significance of DRD2 in neuro-
psychiatric disorders, further analysis included a
comparison of the distributions of the three polymorphisms
between patients with and without neuropsychiatric symp-
toms and signs, and between patients with neuropsychiatric
presentation and patients with dystonic symptoms (most
severe neurologic presentation). All analyses of significance
were repeated in the set of patients homozygous for the
H1069Q mutation, a more homogenous WD patient group.
Statistical Analysis
All data were analyzed using Statistica version 9. The
mean, range, percentage, and SD were noted for descriptive
summary statistics. Quantitative variables were compared
using the Mann–Whitney U test. Categorical variables were
compared between groups using the chi-square test and
Fisher’s test; P < 0.05 was considered statistically signifi-
cant. For the multiple comparisons, hypothesis testing was
performed using the Bonferroni correction (the P-value
divided by the total number of pairwise comparisons) to
correct for the chance that in multiple comparisons the null
hypothesis would be rejected by chance. For three poly-
morphisms, the level of significance was equal to 0.008.
Results
Polymorphisms and WD Clinical Manifestations
In our group of 97 symptomatic patients, 31 had both
neuropsychiatric and hepatic manifestations at onset, 32
had only neurological, and 34 had only hepatic symptoms
and signs. In total, 63 patients had neuropsychiatric
symptoms; among them, 21 had dystonia.
In WD patients and control subjects, no significant devi-
ation from the Hardy–Weinberg equilibrium form was found
for ANKK TaqIA (rs1800497; WD patients, A1/A1 ¼ 2,
A1/A2 ¼ 33, A2/A2 ¼ 62; control subjects, A1/A1 ¼ 3,
A1/A2 ¼ 28, A2/A2 ¼ 69; chi-squared ¼ 0.006, degrees of
freedom (d.f). ¼ 1, P < 0.093), DRD2 PROM –141 C
Table 2 SNPs, primers, and PCR products
SNP ID Position Primer and sequence PCR product RE DNA variant Allele Fragment size (bp)
rs1800497 11 q23.2 F: 5'-CTT GCC CTC TAG
GAA GGA CAT
310 Taq1 T/C T 310
ANKK C 180
R: 5'-ACC TTC CTG AGT
GTC ATC AAC C
130
rs1799732 11 q23.1 F: 5'-CAA CCC TGG CTT
CTG AGT CC
207 Mval 141 ins/del C 207
Promoter R: 5'-GAG CTG TAC CTC
CTC GGC GAT C
– 177
rs1236428 11 q23.1 F: 5'-GCC TGT CCT CCC
CGG CTC TG
349 Hpa II A/G A 349
Ex 8 R: 5'-GGC AGT GAG GAG
CAT GGA GCC AAC
G 282
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Ins/Del (rs1799732; WD patients, Ins/Ins ¼ 83, Ins/Del ¼ 14,
Del/Del ¼ 0; control subjects Ins/Ins ¼ 80, Ins/Del ¼ 20,
Del/Del ¼ 0; chi-squared ¼ 0.614, d.f. ¼ 1, P < 0.433),
and DRD2 Ex8 (rs12364283; WD patients, A/G ¼ 52,
A/A ¼ 40, G/G ¼ 5; control subjects, A/G ¼ 43,
A/A ¼ 52, G/G ¼ 5; chi-squared ¼ 1.234, d.f. ¼ 1,
P < 0.266). We did not detect an impact of these
polymorphisms on the clinical manifestation of WD at
onset (Table 3).
Polymorphisms and Age at First WD Symptom Onset
The mean age of all patients at the first signs of WD was
25.1  8 years (range 7–57 years). We found a significant
association only between rs1799732 polymorphism and age
of onset of WD neuropsychiatric symptoms – carriers of
the deletion (Del+) allele of the 141 C Ins/Del polymor-
phism presented earlier onset of WD neuropsychiatric signs
by 6 years compared with Del  carriers (22.5 vs.
28.3 years; P ¼ 0.035; Table 4).
Homozygous p.H1069Q Patients: Polymorphisms, Clinical
manifestation, and Age of Symptom Onset
WD genotyping of 97 symptomatic WD patients revealed
that 43 patients were homozygous for the p.H1069Q
mutation, 36 patients were compound heterozygous, and
18 patients were negative for the p.H1069Q mutation. We
did not detect an impact of polymorphisms on the clinical
WD manifestation in p.H1069Q homozygous patients
(Table 5). Due to the very small group of patients that
were homozygous for p.H1069Q mutations in the dystonic
group (n ¼ 3), we did not assess these patients separately.
However, among WD p.H1069Q patients, we detected a
statistically significant effect of the DRD2 –141 C Ins/Del
polymorphism. In this homogenous group, Del + allele
carriers presented earlier onset of any WD symptoms by
9 years (20.1 vs. 29.4 years; P ¼ 0.019); furthermore, the
subset of these patients with neuropsychiatic signs pre-
sented with symptom onset 14 years earlier (18.4 vs.
32.2 years; P ¼ 0.001; Table 6).
Table 3 Distribution of neuropsychiatric and dystonia symptoms and signs in WD patients according to DRD2 polymorphism
ANKK TaqI (A1 allele) DRD2 PROM 141 C deletion
DRD2 Ex 8 (A/A vs. A/G
and G/G)
Patients symptoms and signs: A1 A2 Del Del+ A/A A/G and G/G
(n ¼ 35) (n ¼ 62) (n ¼ 83) (n ¼ 14) (n ¼ 54) (n ¼ 43)
Not neuropsychiatric (n ¼ 34) 14 (41 %) 20 (59 %) 31 (91 %) 3 (9 %) 20 (59 %) 14 (41 %)
Neuropsychiatric (n ¼ 63) 21 (33 %) 42 (66 %) 52 (82 %) 11 (17 %) 34 (54 %) 29 (46 %)
Neuropsychiatric with dystonia (n ¼ 21) 9 (43 %) 12 (57 %) 18 (86 %) 3 (14 %) 11 (52 %) 10 (48 %)
Neuropsychiatric without dystonia (n ¼ 42) 12 (29 %) 30 (71 %) 34 (80 %) 8 (20 %) 23 (54 %) 19 (46 %)
Data do not sum to 100 % due to rounding errors. There were no statistically significant differences according to polymorphism or WD
clinical form.
Table 4 Age of symptom onset in patients with presence/absence of neuropsychiatric signs and symptoms according to DRD2 polymorphism
ANKK Taq1 (A1 allele)
DRD2 PROM 141 C
deletion
DRD2 Ex 8 (A/A vs. A/G
and G/G)
Clinical manifestation and age of
symptoms and signs onset
A1 A2 Del Del+ A/A A/G and G/G
(n ¼ 35) (n ¼ 62) (n ¼ 83) (n ¼ 14) (n ¼ 54) (n ¼ 43)








































a Significant difference in age at onset of symptoms (P ¼ 0.035) between DRD2 PROM 141 C del, Del + positive vs. negative patients.
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Discussion
In the present investigation, we identified a significant impact
of the DRD2 PROM –141 C Ins/Del (rs1799732) polymor-
phism on WD clinical neuropsychiatric presentation. We were
thus able to partially confirm our initial hypothesis that
changes in dopaminergic neurotransmission due to DRD2
polymorphism could be important for clinical neuropsychiatric
manifestation. Carriers of the Del + allele of the –141 C Ins/
Del polymorphism presented earlier onset of WD neuro-
psychiatric symptoms by almost 6 years compared with the
Del variant. This unfavorable effect of the –141 C Ins/Del
polymorphism was even more pronounced in WD p.H1069Q
homozygous patients, as the Del + allele carriers presented
earlier onset of any WD symptoms by nearly 9 years and
neuropsychiatric symptoms by nearly 14 years. Our analysis
suggests that the Del + effect was restricted to neuropsychi-
atric manifestation. Additionally, we did not find any
correlation between WD manifestation and the two other
studied polymorphisms ANKK TaqIA (rs1800497) and DRD2
Ex8 (rs12364283). The p.H1069Q effect observed in our
study could be explained by the fact that compared to other
mutations, p.H1069Q ATP7B exerts a relatively mild effect on
functions of ATPase 7B (Stapelbroek et al. 2004; Gromadzka
et al. 2005) and it is possible that the WD phenotypes of
patients possessing more severe ATP7B mutations are
modulated by other factors to a lesser degree.
In WD, most neuropsychiatric symptoms are due to
basal ganglia copper accumulation and the secondary
damage to affected structures (dystonia, parkinsonism, and
others) or prefrontal cortex disturbances (Magalhes et al.
1994; Schlaug et al. 1994; Nyberg et al. 1982; Oder et al.
1993; Seniow et al. 2002), as both of these areas involve
the dopaminergic system (Vallone et al. 2000). Autopsies
and radiological and laboratory investigations of WD cases
have found reduced striatal dopamine and hydroxylase
tyrosine levels (Nyberg et al. 1982), as well as reduced
dopamine D2 receptor density (Oder et al. 1996; Schlaug
et al. 1994). However, treatment with dopamine agonists or
levodopa had no effect, probably due to the presence of
both pre- and postsynaptic dopaminergic damage (Frankel
et al. 1989; Jeon et al. 1998). The density of DRD2
postsynaptic receptors tends to increase during anti-copper
treatment (Schlaug et al. 1994), suggesting that the
Table 5 Distribution of neuropsychiatric symptoms and signs in WD patients according to DRD2 polymorphism in 43 p.H1069Q homozygous
patients
ANKK Taq1 (A1 allele) DRD2 PROM 141 C deletion DRD2 Ex 8 (A/A vs. A/G and G/G)
Clinical manifestation (symptoms
and signs) (n ¼ 43)
A1 A2 Del Del+ A/A A/G and G/G (n ¼ 19)
(n ¼ 16) (n ¼ 27) (n ¼ 36) (n ¼ 7) (n ¼24)
Not neuropsychiatric (n ¼ 15) 6 (40 %) 9 (60 %) 13 (86 %) 2 (13 %) 8 (53 %) 7 (46 %)
Neuropsychiatric (n ¼ 28) 10 (35 %) 18 (65 %) 23 (82 %) 5 (18 %) 16 (57 %) 12 (42 %)
Data do not sum to 100 % due to rounding errors. There were no statistically significant differences according to polymorphism and WD
clinical form.
Table 6 Age of symptom onset in all WD patients, and according to the presence/absence of neuropsychiatric symptoms and signs and to DRD2
polymorphism in p.H1069Q homozygous patients
ANKK Taq 1 (A1 allele)
DRD2 PROM 141 C
deletion
DRD2 Ex 8 (A/A vs. A/G
and G/G)
Clinical manifestation and age of
symptoms and signs onset (years)
A1 A2 Del Del+ A/A A/G and G/G
(n ¼ 19)(n ¼ 16) (n ¼ 27) (n ¼ 36) (n ¼ 7) (n ¼ 24)






































a Statistically significant difference (P ¼ 0.019) in age at onset of symptoms between DRD2 PROM 141 C del, Del + positive and negative
patients (all WD patients).
b Statistically significant difference (P ¼ 0.001) in age at onset of symptoms between DRD2 PROM 141 C del, Del + positive and negative
patients (patients with neuropsychiatric symptoms and signs).
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dopamine D2 receptor pathway may be critical to WD
clinical presentation. Furthermore, DRD2 polymorphisms
are predictive of the dopamine receptor D2 density in the
striatum (Noble 2003; Ritchie and Noble 2003), which may
also affect WD neuropsychiatric manifestation.
Based on the previously reported clinical significance of
the polymorphisms ANKK TaqIA and DRD2 Ex8 (Table 1),
we thought that the decreased DRD2 density in the striatum
in TaqI A1 allele carriers or reduced expression of DRD2 in
Ex8 A/A genotype may worsen dopaminergic neurotrans-
mission leading to earlier onset of neuropsychiatric WD
signs, but our data did not confirm this hypothesis. The
ANKK TaqIA and DRD2 Ex8 polymorphisms had no
impact on WD clinical presentation. We also did not
identify a relationship between dystonic manifestation of
WD and ANKK TaqI or DRD2 Ex8 polymorphisms as we
had expected. This lack of a detected association may be
due to our small patient sample, or there may be a different
etiology of neuropsychiatric symptoms in WD via other
mechanisms involving DRD2.
Previous reports of the clinical significance of the DRD2
141 C Ins/Del polymorphism have been conflicting
(Table 1). According to some studies (Jonsson et al. 1999;
Zhang et al. 2010) Del + carriers may have higher numbers
of DRD2 receptors in the striatum. A decrease of
postsynaptic DRD2 is usually observed during WD (Oder
et al. 1996; Schlaug et al. 1994), and increase is observed
during chelating treatment (Schlaug et al. 1994). According
to these observations, we should have found a protective
effect of the Del + allele on neuropsychiatric presentation
(increased number of DRD2) in WD, but we did not. On
the contrary, we found that the Del + genotype accelerated
the onset of neuropsychiatric symptoms. This unfavorable
effect of the Del + allele may be explained by other
mechanisms – like changes in receptor affinity, changes in
receptor structure, interactions with other genes or environ-
mental factors, or D2 receptor hyposensitivity, leading to a
decreased effect of dopaminergic transmission. Another
possible mechanism with such an effect could be connected
with the impact of the DRD2 141 C Ins/Del polymor-
phism on the number of presynaptic D2 receptors (Vallone
et al. 2000). According to such a hypothesis, Del + allele
carriers could present increased numbers of such receptors,
thus providing WD patients with stimulation of D2
presynaptic receptors with low doses of dopamine, which
could further reduce dopamine release and dopaminergic
cell firing and finally reduce locomotor functions and lead
to neuropsychiatric WD presentation (Vallone et al. 2000).
Further studies to confirm such hypotheses are very
important, because such information could help establish
group of WD patients in whom treatment with higher dose
of levodopa would be beneficial (Del + carriers). Future
investigations of this topic should include assessment of
DRD2 density in radiological studies.
Our study has a few limitations. The first is the small
number of patients included and the further limited number
of SNPs analyzed. However, it should be noted that WD is a
rare disease, and the number of patients in our study is very
similar to that in many other WD or DRD2 gene
polymorphism studies (Schiefermeier et al. 2000; Kishida
et al. 2004). This is the first pilot study of DRD2 gene
polymorphism in WD, so we tried to assess the most
important DRD2 SNPs in neuropsychiatric disorders (espe-
cially movement disorders). Furthermore, data are conflicting
regarding the impact of the DRD2 141 C Ins/Del
polymorphism on DRD2 density; without more specific
studies (PET), we cannot confirm the etiology of the impact
of the Del + allele on WD neuropsychiatric presentation. In
the present report, we can only hypothesize about the impact
on DRD2 expression based on some previous studies (Zhang
et al. 2010; Jonsson et al. 1999), but these possibilities
should be further investigated especially in WD.
In summary, our findings suggest that the DRD2 141 C
Ins/Del polymorphism affects WD neuropsychiatric presen-
tation, probably through disruption of the balance of
dopamine neurotransmission that makes these patients more
sensitive to basal ganglia intoxication by copper accumula-
tion. Further studies of DRD2 SNPs with dopamine
receptor imaging in WD patients are needed to better
understand the mechanisms of such phenotypic effects.
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